COVID 19 Conquered, CEO Of BioNTech Wants Company To Go Back

COVID 19 is conquered, at least for now and BioNTech’s CEO wants to turn back his focus into his original niche, cancer.

Dr. Ugur Sahin is experimenting with the mRNA technology BioNTech introduced in collaboration with Pfizer, to improve his challenging cancer treatment; CAR-T therapy.

COVID 19 Conquered, CEO Of BioNTech Wants Company To Go Back

Dr. Sahin wants to use a particular mRNA vaccine to modify his treatment for cancer. This way, he aims to add up to its safety. He also wants to make it affordable.  He is even presenting the results of the first phase of its clinical trial At a meeting convened by the Society for Immunotherapy of Cancer meeting in Washington DC.

He told during an interview with a reputed channel; they treat cancer. And they are passionate to offer better treatments for the disease.

COVID 19 Conquered, CEO Of BioNTech Wants Company To Go Back

CAR-T stands for chimeric antigen receptor T-cell therapy. During the treatment, doctors take certain immune cells from the patient named T-cells. They genetically alter these cells and make them capable of destroying cancerous cells. Done this, they infuse back the cells to the patient’s body.

At present, the therapy is expensive and rare. FDA has approved only a limited number of such therapies. Each treatment costs almost $400,000.

These treatments work great for cancers that affect blood. And Sahin is trying to make it work for real tumors. The thing that worries him is toxicity. The patient may experience complications that can be fatal.  The most prominent among them are cytokine release syndrome and swelling of the mind. And an try to make use of this therapy for actual tumors could show harmful.

Most cancers-specific targets are fairly low in quantity. This makes it tough for medical doctors to develop a secure and efficient therapy for a similar. Discovering a goal that doesn’t generate toxicity is the best problem that scientists face within the discipline.

BioNTech plans to make use of a selected molecule known as claudin 6. This isn’t lively in wholesome cells however is lively in cancerous cells. This molecule, nevertheless, is activated and is seen in a number of cancers like testicular most cancers, ovarian most cancers, endometrial most cancers, and the share of different tumors, a smaller proportion of abdomen most cancers, lung most cancers, and of some kinds of sarcomas.

In keeping with him, the goal is clearly seen like white and black. It’s not lively in wholesome cells and has a robust expression in cancerous cells. The corporate additionally has developed a robust antibody for use as a receptor for this therapy.

The info submitted, nevertheless, solely included 9 sufferers affected by testicular, ovarian, and endometrial cancers. There was additionally a affected person with gentle tissue sarcoma.

In keeping with Dr. Sahin, the therapy is secure. They don’t see toxicity, however an encouraging exercise; the shrinking of the tumor. The exercise is a small signal, they report. That is the place the mRNA vaccine involves be of help. Dr. Sahin hopes to make use of it to ask T-cells to search for cancerous cells within the physique and destroy them. This, in keeping with him will work in the identical manner as vaccines. It locates and assaults germs earlier than they will make you in poor health.

The impact of this therapy goes to be enormous. Superior ovarian cancers nonetheless stay curable. With this therapy, it turns into potential. Moreover, the corporate says that it’s inexpensive and might roll out on a big scale if required.

The most cancers therapy, nevertheless, is kind of costly. However Dr. Sahin hopes that he would make it inexpensive for a mean particular person.

They deal with most cancers and don’t wish to develop a therapy meant solely for the wealthiest. He, nevertheless, refused to reply the query of how he plans to make the therapy cost-effective.

Newest posts by Nikki Attkisson (see all)

Leave a Reply

Your email address will not be published.